Is CAPR or CELU more undervalued in 2026?

CirclFi compares Capricor Therapeutics, Inc. (CAPR) and Celularity Inc. (CELU) using 13 institutional-grade valuation models. CAPR has a Quality of Company score of 6.9/10 while CELU scores 4.9/10.

Which is a better buy — CAPR or CELU?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CAPR and CELU valuations compare?

CAPR at $29.96 and CELU at $1.01 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CAPR vs CELU Valuation Comparison 2026 — Intrinsic Value Analysis

CAPR

Pharmaceutical Preparations

Capricor Therapeutics, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$29.96

Last close

Models

12/13

Active

CELU

Pharmaceutical Preparations

Celularity Inc.

Quality

4.9

out of 10

Value Trap

LOW

Price

$1.01

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	CAPR Fair Value	CAPR Upside	CELU Fair Value	CELU Upside
Bayesian DCF	Intrinsic	$6.55	-78.1%	—	—
Earnings Power Value	Intrinsic	$15.35	-56.5%	$3.41	+256.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$27.24	-9.1%	$3.98	+293.9%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CAPR vs CELU — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CAPR vs CELU — Which Stock Is More Undervalued?

CAPR scores higher with a 6.9/10 quality rating vs CELU's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Capricor Therapeutics, Inc. (CAPR) and Celularity Inc. (CELU) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CAPR currently trades at $29.96 with a QOC of 6.9/10, while CELU trades at $1.01 with a QOC of 4.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).